1-叔丁基-1H-咪唑 | 45676-04-8

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-叔丁基-1H-咪唑
• 中文别名: 1-叔丁基咪唑
• 英文名称: 1-(tert-butyl)-1H-imidazole
• 英文别名: N-tert-butylimidazole；1-t-butyl imidazole；1-(tert-butyl)imidazole；tert-butylimidazole；1-(t-butyl)-1H-imidazole；1-t-Butylimidazole；1-tert-butylimidazole
• CAS: 45676-04-8
• 化学式: C₇H₁₂N₂
• 分子量: 124.186
• InChiKey: AMQKPABOPFXDQM-UHFFFAOYSA-N

物化性质

• 沸点：
  105°C/12mmHg(lit.)
• 密度：
  0.92±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存放于惰性气体中，避免与空气接触。

制备方法与用途

用途

1-叔丁基咪唑可以作为医药合成中的中间体。它可通过N-叔丁基咪唑与氯代叔丁烷及氢化钠反应制备，进而用于生成化合物1-二苯基膦甲基-3-叔丁基咪唑-2-烯。

反应信息

• 作为反应物：
  描述：

  1-叔丁基-1H-咪唑 在 copper(l) iodide 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 24.0h， 生成 4-((1-tert-butyl)-1H-imidazolium-3-yl)methyl-1-(2,6-diisopropylphenyl)-3-methyl-1H-1,2,3-triazol-3-ium bromide trifluoromethanesulfonate
  参考文献：
  名称：

  Unsymmetrical Dicarbenes Based on N-Heterocyclic/Mesoionic Carbene Frameworks: A Stepwise Metalation Strategy for the Generation of a Dicarbene-Bridged Mixed-Metal Pd/Rh Complex

  摘要：

  A pair of linked imidazolium/triazolium salts have been prepared using copper-catalyzed azide-alkyne cycloaddition (CuAAC or "click" chemistry) and methylation protocols, producing a precursor for bidentate N-heterocyclic carbene (NHC)/mesoionic carbene (MIC) ligands, representing a rare example of an NHC/MIC hybrid. Metalation of one-half of this dicationic species using the basic ligand-containing [Pd(OAc)(2)] in the presence of potassium iodide or half an equivalent of [Rh(mu-OMe) (COD)](2) yields NHC-anchored/pendent triazolium species of Pd or Rh, respectively. The pendent Pd species can be further functionalized through iodide substitution by various monophosphines, which preferentially adopt a cis or trans arrangement depending on the bulk of the anchored NHC substituent. Combining these "internal-base" and "pendent" strategies, the pendent MIC(H)(+) arm of the trans-triethylphosphinefunctionalized Pd species can be metalated by [Rh(mu-OMe)(COD)](2), resulting in the generation of a hybrid NHC/MIC-bridged mixed-metal Pd/Rh species. This complex represents the first example of a hybrid unsymmetrical dicarbene bridging two different metals.

  DOI：

  10.1021/om3004543
• 作为产物：
  描述：

  叔丁基异硫氰酸酯 在 硫酸 、 硝酸 作用下， 以 乙醇 为溶剂， 反应 4.25h， 生成 1-叔丁基-1H-咪唑
  参考文献：
  名称：

  Quaternary salts of 2-[(hydroxyimino)methyl]imidazole. 3. Synthesis and evaluation of (alkenyloxy)-, (alkynyloxy)-, and (aralykyloxy)methyl quaternarized 2-[(hydroxyimino)methyl]-1-alkylimidazolium halides as reactivators and therapy for soman intoxication

  摘要：

  A series of structurally related monosubstituted 1-[(alkenyloxy)methyl]-, 1-[(alkynyloxy)methyl]-, and 1-[(aralkyloxy)methyl]-2-[(hydroxyimino)methyl]-3-methyli midazolium halides were prepared and evaluated. All new compounds were characterized with respect to (hydroxyimino)methyl acid dissociation constant, nucleophilicity, and octanol-buffer partition coefficient. The alkynyloxy-substituted compounds were also evaluated in vitro with respect to reversible inhibition of human erythrocyte (RBC) acetylcholinesterase (AChE) and kinetics of reactivation of human AChE inhibited by ethyl p-nitrophenyl methylphosphonate (EPMP). In vivo evaluation in mice revealed that coadministration of alkynyloxy-substituted imidazolium compounds with atropine sulfate provided significant protection against a 2 x LD50 challenge of GD. For the alkynyloxy-substituted imidazolium drugs there is a direct relationship between in vitro and in vivo activity: the most potent in vivo compounds against GD proved to be potent in vitro reactivators against EPMP-inhibited human AChE. These results differ from the observations made on the sterically hindered imidazolium compounds (see previous article) and suggest that several antidotal mechanisms of protective action may be applicable for the imidazolium aldoxime family of therapeutics. The ability of the alkynyloxy substituents to provide life-saving protection against GD intoxication was not transferable to the pyridinium or triazolium heteroaromatic ring systems.

  DOI：

  10.1021/jm00122a035

文献信息

• SUBSTITUTED SULFONAMIDE COMPOUNDS
  申请人：OBERBOERSCH Stefan

  公开号：US20080153843A1

  公开（公告）日：2008-06-26

  Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.

  磺胺取代物，其制备方法，含有这些化合物的药物组合物，以及磺胺取代物在治疗或抑制疼痛和/或各种疾病或疾病状态中的用途。
• Iridium and Rhodium Complexes Containing Enantiopure Primary Amine-Tethered <i>N</i>-Heterocyclic Carbenes: Synthesis, Characterization, Reactivity, and Catalytic Asymmetric Hydrogenation of Ketones
  作者：Kai Y. Wan、Florian Roelfes、Alan J. Lough、F. Ekkehardt Hahn、Robert H. Morris

  DOI：10.1021/acs.organomet.7b00915

  日期：2018.2.12

  a bimetallic iridium compound with (S,S)-11 as the bridging ligand. This compound contains interesting NH···Cl and NH···Ir noncovalent intramolecular interactions. Salt (S,S)-12·HPF6 reacts with silver oxide to yield [Ag2((S,S)-12)2](PF6)2 (20). Reagent 20 serves as an efficient transmetalation reagent to deliver to each rhodium in [RhCl(cod)]2 1 equiv of (S,S)-12 as a bidentate ligand to give [Rh(cod)((S

  咪唑鎓盐[（S，S）-t BuNC 3 H 3 NCHPhCHPhNH 2 ] PF 6，（S，S）-11· HPF 6是对映纯的“ Kaibene”配体t Bu-Kaibene （（S，S）-11在N-杂环卡宾（NHC）环-氮原子上具有叔丁基。通过将手性环状氨基磺酸酯与1-叔丁基咪唑回流，可以高产率和高纯度地制备它。同样（（S，S）-12·在咪唑鎓环氮原子上具有异氰酸酯基的HPF 6以相同的方式制备，并用作Mes-Kaibene，（S，S）-12的来源。这些双齿Kaibene配体具有NHC和被手性接头隔开的伯胺。盐（S，S）-11· HPF 6或（S，S）-12· HPF 6与碱和AgI或CuI反应生成总共四个M（Kaibene） 2I化合物（M = Ag或Cu）。在22°C下，胺官能化的咪唑鎓阳离子经过氧化加成到[IrCl（cod）] 2（cod = 1,5-环辛二烯）中的铱（I），生
• SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190224188A1

  公开（公告）日：2019-07-25

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式(I)的化合物及其药学上可接受的盐： 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• ISOXAZOLINE DERIVATIVES AS INSECTICIDES
  申请人：Pitterna Thomas

  公开号：US20120316124A1

  公开（公告）日：2012-12-13

  The present invention relates to compounds formula (I), wherein P is P1, P2, heterocyclyl or heterocyclyl substituted by one to five Z; and wherein A 1 , A 2 , A 3 , A 4 , G 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 17 , R 18 , R 19 and R 20 are as defined in claim 1 ; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising the compounds of formula (I) and to methods of using the compounds of formula (I) to control insect, acarine, nematode and mollusc pests.

  本发明涉及化合物式（I），其中P为P1、P2、杂环烷基或被1至5个Z取代的杂环烷基；以及其中A1、A2、A3、A4、G1、R1、R2、R3、R4、R5、R6、R17、R18、R19和R20如权利要求1所定义；或其盐或N-氧化物。此外，本发明涉及制备化合物式（I）的过程和中间体，包括化合物式（I）的杀虫剂、杀螨剂、杀线虫剂和杀软体动物剂组合物，以及使用化合物式（I）控制昆虫、螨虫、线虫和软体动物害虫的方法。
• CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Araxes Pharma LLC

  公开号：US20180015087A1

  公开（公告）日：2018-01-18

  Conjugates of a cereblon-binding compound and compounds having modulatory activity against G12C mutant KRAS, HRAS or NRAS G12C proteins are provided. Methods associated with preparation and use of such conjugates, pharmaceutical compositions comprising such conjugates and methods to modulate the activity of G12C mutant KRAS, HRAS or NRAS G12C proteins for treatment of disorders, such as cancer, are also provided.

  提供了与谷氨酰脑结合化合物和具有调节活性对抗G12C突变KRAS、HRAS或NRAS G12C蛋白的化合物的共轭物。还提供了与制备和使用这种共轭物相关的方法，包括含有这种共轭物的药物组合物以及调节G12C突变KRAS、HRAS或NRAS G12C蛋白活性的方法，用于治疗癌症等疾病。